Exact Sciences Licenses Mayo Clinic IP; Closes $8.2M Placement | GenomeWeb

NEW YORK (GenomeWeb News) - Exact Sciences said today that it has signed a deal with the Mayo Clinic for exclusive rights to intellectual property related to stool-based screening for colorectal cancer.

The company said that it has also closed an $8.2 million private placement of 4.3 million shares of its common stock.

Exact gained exclusive rights to technology developed by the Mayo Clinic's David Ahlquist relating to sample processing, analytical testing, and data analysis for non-invasive, stool-based DNA screening for colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.